<DOC>
	<DOCNO>NCT01119105</DOCNO>
	<brief_summary>This Phase II , multi-center , randomize , double-blind study compare safety efficacy two dose BC-3781 versus vancomycin patient acute bacterial skin skin structure infection .</brief_summary>
	<brief_title>Study Comparing Safety Efficacy Two Doses BC-3781 v Vancomycin Patients With Acute Bacterial Skin Skin Structure Infection ( ABSSSI )</brief_title>
	<detailed_description>The purpose study determine efficacy 2 dose regimen BC-3781 versus license medicinal product vancomycin 5 14 day . The population study patient acute bacterial skin skin structure infection ( ABSSSI ) receive treatment one two dose BC-3781 vancomycin , standard treatment condition .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Male female patient &gt; 18 Documented acute bacterial skin skin structure infection Uncomplicated skin skin structure infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>acute bacterial skin skin structure infection</keyword>
	<keyword>bacteria</keyword>
</DOC>